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Abstract
Background: Transcriptome analysis shows that the chemotherapy innate resistance state of
tumors is characterized by: poorly dividing tumor cells; an increased DNA repair; an increased drug
efflux potential by ABC-transporters; and a dysfunctional ECM. Because chemotherapy resistance
involves multiple genes, epigenetic-mediated changes could be the main force responsible of this
phenotype. Our hypothesis deals with the potential role of epigenetic therapy for affecting the
chemotherapy resistant phenotype of malignant tumors.
Presentation of the hypothesis: Recent studies reveal the involvement of DNA methylation
and histone modifications in the reprogramming of the genome of mammalian cells in cancer. In this
sense, it can be hypothesized that epigenetic reprogramming can participate in the establishment
of an epigenetic mark associated with the chemotherapy resistant phenotype. If this were correct,
then it could be expected that agents targeting DNA methylation and histone deacetylation would
by reverting the epigenetic mark induce a global expression profile that mirror the observed in
untreated resistant cells.
Testing the hypothesis: It is proposed to perform a detailed analysis using all the available
databases where the gene expression of primary tumors was analyzed and data correlated with the
therapeutic outcome to determine whether a transcriptome profiling of "resistance" is observed.
Assuming an epigenetic programming determines at some level the intrinsic resistant phenotype,
then a similar pattern of gene expression dictated by an epigenetic mark should also be found in
cell acquiring drug resistance. If these expectations are meet, then it should be further investigated
at the genomic level whether these phenotypes are associated to certain patterns of DNA
methylation and chromatin modification. Once confirmed the existence of an epigenetic mark
associated to either the intrinsic or acquired chemotherapy resistant phenotype, then a causal
association should be investigated. These preclinical findings should also be tested in a clinical
setting.
Implications of the hypothesis: Our hypothesis on the ability of epigenetic therapy to revert
the epigenetic changes leading to a transcritome profile that defines the resistant state will
eventually be a more rational and effective way to treat malignant tumors.
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Background
In the cancer arena, the phenomenon of chemotherapy
resistance has being for years, the focus of intensive
research with the aim to increase its understanding and
hopefully for finding out novel therapies to overcome it.
In the past years, and before the introduction of methods
for global genomic analysis, the phenomenon was mostly
studied at the single gene level, for instances, the mdr gene
and related members [1]; the detoxifying systems such as
the glutathione-S-transferase families [2]; and antiapop-
totic genes [3] just to mention some. Nevertheless, these
models turned out to be a quite simplistic approximation
of the chemotherapy resistance as shown by in general
poor clinical results of agents against individual targets
such as mdr blockers [4,5].
Thus, the chemotherapy resistant phenotype of cancer
cells is by no means the result of a single gene alteration;
hence, the phenomenon should be studied at a global
genomic level. Such an assumption is backed by the
knowledge that cancer cells do contain multiple gene
genetic defects, namely mutations, deletions, duplica-
tions, translocations, etc, as well as epigenetic aberrations,
such as alterations at DNA methylation and histone post-
transductional modifications. Both the genetic and epige-
netic alterations are not static and must act in concert in
order to maintain the malignant "homeostasis" and also
to cope with the cytotoxity induced by chemotherapy or
radiation therapy [6,7].
Cancer is a highly heterogeneous disease however; most
malignant tumors share the ability of being intrinsically
resistant to chemotherapy and to acquire it during treat-
ment. Microarray technology has the potential to better
assess the complexity, redundancy and interdependence
in biological pathways involved in drug resistance how-
ever, most high-throughput gene expression profiling
studies with microarrays are being directed to dissect the
molecular cancer pathways in the aim to improve current
tumor classifications and to discover novel diagnostic and
therapeutic potential targets [8-10]. Common to all of
these studies is the fact that models investigated do not
address mechanisms that contribute to innate drug resist-
ance, but rather test hypotheses on how drug exposure
induce resistance states. A recent study on transcriptional
profiles of clinical samples collected from colorectal can-
cer patients prior to their exposure to a combined chemo-
therapy shows that 679 genes discriminates between drug
resistance and sensitivity states. In addition, through tran-
scriptome analysis and functional annotation, authors
were able to suggest that the innate resistant state may be
characterized by: poorly dividing tumor cells as deduced
from observed accumulation of cells in mid-G1 phase and
decreased DNA replication processivity; an increased
DNA repair associated with cell cycle delay in late S and
G2 phases preventing occurrence of mitotic catastrophe
and cell apoptosis; an increased drug efflux potential by
ABC-transporters pre-existing to drug exposure; and a dys-
functional extracellular matrix (ECM) with decreased
renewal ability of ECM and basement membrane compo-
nents, most likely resulting in decreased stimulation of
angiogenesis [11].
These data clearly demonstrate that chemotherapy resist-
ance requires of changes in expression of a large number
of genes. In this regard, clonal selection of cells by genetic
changes would hardly explain the resistant phenotype,
instead epigenetic-mediated changes could be the driving
force as by one hand, they provide a mechanism whereby
expression of multiple genes could be affected simultane-
ously and secondly, epigenetic changes can be a rapid
process as a result, resistance may therefore arise rapidly
following treatment with chemotherapy in the case of
acquired resistance [12-14]. In contraposition of genetic
defects, the reversible nature of the epigenetic aberrations
constitutes a very attractive therapeutic target and as such,
a number of inhibitors of DNA methylation and histone
deacetylases are currently being evaluated in cancer ther-
apy either alone or in combination, as there is clear that
these drug have a synergistic effect upon gene expression
and tumor growth [15-17]. A recent study [18] reported
on the global gene expression profile of the resistant colon
carcinoma cell line SW480 [19-21] induced by the com-
bined treatment of hydralazine, a DNA methylation
inhibitor with valproic acid, a histone deacetylase inhibi-
tor. The gene expression profile from the resistant colon
carcinoma tumors and from the resistant colon cancer cell
line treated with epigenetic agents led us to put forward
the hypothesis on the potential role that epigenetic ther-
apy has to revert the chemotherapy resistant phenotype of
malignant tumors.
Presentation of the hypothesis
Epigenetic control of gene activity is widespread in the
genome of eukaryotic cells and leads to persistent gene
silencing or gene expression. This control is implemented
by changes in the methylation status of DNA and by chro-
matin modifications. The epigenetic modifications effi-
ciently control the state of gene expression in the genome
by inducing stable silencing of some genes and promoting
activation of others [22,23]. The epigenetic control of
gene expression is heritable through cell division, but
reversible, because it does not involve DNA sequences.
Recent studies reveal the involvement of DNA methyla-
tion and histone modifications in the reprogramming of
the genome of mammalian cells in cancer [24-26]. In this
sense, it can be hypothesized that epigenetic reprogram-
ming can participate in the establishment of an epigenetic
mark associated with the chemotherapy resistant pheno-
type. If this were correct, then it could be expected thatMolecular Cancer 2006, 5:27 http://www.molecular-cancer.com/content/5/1/27
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agents targeting DNA methylation and histone deacetyla-
tion would by reverting the epigenetic mark induce a tran-
scriptome profile that mirror the observed in untreated
resistant cells.
This hypothesis surges from the comparisons in the gene
expression profiling between tumors intrinsically resistant
to chemotherapy [11] and the expression data from the
colon carcinoma cell line SW480 treated with the DNA
methylation and the histone deacetylase inhibitor
hydralazine and valproic acid respectively [18] employing
FatiGO module from Babelomics suite [27,28]. FatiGO is
a web based tool which map biological knowledge on sets
of genes to extract relevant gene ontology (GO) terms for
a group of genes with respect to a reference set. The terms
are considered to be relevant upon the application of a
Fisher's exact test or 2 × 2 contingency tables. We observed
that several cellular processes were inversely regulated as
shown in Figure 1 where it seems to be a mirror image
between these data. To make this comparison, we took
only up-regulated genes reported as supplementary infor-
mation by Gaurdens et al, (317 genes) and by Chavez-
Blanco et al, (352 genes). Both lists of genes were down-
loaded from these publications [11,18] and then data
loaded into the FatiGO data mining tool. The retrieved
information was then submitted for finding differences in
the distribution of GO biological process terms between
both groups of genes. The biological processes selected
and showed in Figure 1 were taken as significant if p values
< 0.01; except for cell proliferation and cell adhesion
terms which showed a p value of 0.15 and 0.23, respec-
tively.
Testing the hypothesis
The analysis of the published data concerning the expres-
sion patterns in colorectal carcinoma patients and the
colon carcinoma cell line SW480 strongly suggests that
the potential ability of epigenetic agents to revert and/or
at least to interfere with the epigenetic functioning charac-
terizing the resistant phenotype should be further studied.
In this aim, it is proposed to perform a detailed analysis
using available databases where the gene expression of
Main Gene Ontology terms which are inversely regulated in both phenotypes Figure 1
Main Gene Ontology terms which are inversely regulated in both phenotypes. We used information from "additional files" list-
ing gene expression profile from Gaurdens et al, [11] and Chávez-Blanco et al, [18] then we took 317 and 352 up-regulated 
genes respectively and by means of FatiGO, comparisons in functional annotations were made. 1. Cell cycle; 2. Response to 
DNA damage; 3. Cell proliferation; 4. Cell adhesion; 5. M phase; 6. DNA repair; 7. Regulation of cell proliferation; 8. Regulation 
of cell cycle; 9. DNA metabolism; 10. M phase of mitotic cell cycle; 11. Regulation of progression through cell cycle; 12. 
Immune cell activation; 13. Ubiquitin Cycle.Molecular Cancer 2006, 5:27 http://www.molecular-cancer.com/content/5/1/27
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primary tumors was analyzed and data correlated with the
therapeutic outcome. It means data that from these stud-
ies aimed to the pre-treatment classification into resistant
and sensitive tumor should be dissected and compared to
determine whether the observation raised is a generaliza-
ble phenomenon.
It has been clearly shown that epigenetic changes occur
rapidly upon chemotherapy exposure, thus it can be antic-
ipated that assuming an epigenetic programming deter-
mines at some level the intrinsic resistant phenotype, then
a similar pattern of gene expression dictated by an epige-
netic mark should also be found in cell acquiring drug
resistance. In fact, there are many evidences on the rapid
changes in DNA methylation and chromatin modifica-
tions after cytotoxic chemotherapy in several models [29-
34]. If these expectations are meet when tested with the
appropriate tools, then it should be further investigated at
the genomic level whether these phenotypes are associ-
ated to certain patterns of DNA methylation and chroma-
tin modification. In this regard, there are now several
powerful platforms for this kind of analysis.
Once confirmed the existence of an epigenetic mark asso-
ciated with either the intrinsic or acquired chemotherapy
resistant phenotype, then a causal association should be
investigated. In this regard, chemotherapy resistant malig-
nant cells should be treated with epigenetic agents to then
analyze changes at the phenotype (restoration of sensitiv-
ity), transcriptome and epigenetic marks at global level.
So far, a number of preclinical studies have demonstrated
that either DNA methylation [35,36] of histone deacety-
lase inhibitors [37,38] or in combination [18], reverse
drug resistance or increase the cytotoxicity of anticancer
drugs and radiation. In this regard, currently there are a
number of clinical trials testing epigenetic drugs either
alone or in combination with conventional cytotoxic and
radiation therapy [39]. Multisampling of primary tumors
and/or peripheral blood is fundamental for evaluating the
reversion of the epigenetic changes and their correlation
with patient tumor response and prognosis. Along with
all these investigations proposed, a better dissection of the
contribution of specific epigenetic alterations will require
an individual analysis of each known epigenetic player
such as global DNA methylation, promoter DNA methyl-
ation, specific histone modification (acetylation, methyl-
ation, phosphorylation, etc) as well as changes at other
molecules of the epigenetic machinery such as polycomb
and trithorax groups [40].
Implications of the hypothesis
The confirmation of this hypothesis has obvious implica-
tions in the field of cancer therapy. Generally speaking, we
can name the current era of targeted therapies as ones
directed against a single gene or single gene product, or in
other words, "a single gene approach". This approach as
such, has limitations because of the plasticity of tumor
cell genomes as well as because of the multistep nature of
cancer development where no single genetic mutation is
responsible for the malignant phenotype (except for some
specific neoplasms). This means that even though the
blocking of a single or few abnormalities can induce to the
tumor cell to stop or slow its proliferation, to induce its
differentiation or to undergo apoptosis, eventually tumor
cells will develop resistance to the therapy because of its
ability to bypass such blocking effect by making the
appropriate epigenetic changes modifying the transcrip-
tome. In this sense our hypothesis dealing with the ability
of blocking or reverting the machinery responsible of
these cell strategies to survive will eventually be a more
rational and effective way to deal with the resistant state
of malignant tumors.
Conclusion
The chemotherapy resistant state of cancer cells seems to
be a polygenic phenomenon where epigenetic-mediated
changes could be the driving force leading to this pheno-
type. Our hypothesis deals with the potential role of epi-
genetic therapy for affecting the chemotherapy resistant
phenotype of malignant tumors. Preclinical information
from experimental models using DNA methylation and
histone deacetylase inhibitors suggests that epigenetic
therapy could erase the epigenetic mark associated with
the chemotherapy resistant phenotype and therefore sen-
sitize tumors to chemotherapy.
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